Trial Profile
A phase II study of AZD2171 [cediranib] in breast cancer stage IV (10006202)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Nov 2005 New trial record.